Meanwhile, bortezomib (BTZ), a proteasome inhibitor that has been approved by FDA for the clinical treatment of multiple myeloma (MM),28 was used to restore ATF4 expression in chemoresistant cells. This evidence concerns the gene ATF4 and plasma cell myeloma.